<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00032110</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02459</org_study_id>
    <secondary_id>NCI-2012-02459</secondary_id>
    <secondary_id>CDR0000069258</secondary_id>
    <secondary_id>PHL-003</secondary_id>
    <secondary_id>NCI-5378</secondary_id>
    <secondary_id>PHL-003</secondary_id>
    <secondary_id>5378</secondary_id>
    <secondary_id>N01CM17107</secondary_id>
    <nct_id>NCT00032110</nct_id>
  </id_info>
  <brief_title>Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase II Study of OSI-774 in Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow&#xD;
      the growth of the tumor. Phase II trial to study the effectiveness of erlotinib in treating&#xD;
      patients who have recurrent or metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of erlotinib, in terms of response rate and duration of stable&#xD;
      disease, in patients with recurrent or metastatic colorectal cancer.&#xD;
&#xD;
      II. Determine the toxicity of this drug in these patients. III. Determine the time to&#xD;
      progression and response duration in patients treated with this drug.&#xD;
&#xD;
      IV. Determine the relationships between clinical, pharmacokinetic, and pharmacodynamic&#xD;
      effects of this drug in these patients.&#xD;
&#xD;
      V. Correlate baseline and post-treatment levels of epidermal growth factor receptor, its&#xD;
      downstream signaling components, markers of angiogenesis, and apoptosis in tumor and skin&#xD;
      biopsies with clinical outcome in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral erlotinib once daily. Treatment repeats every 28 days in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients with a complete response (CR) receive&#xD;
      2 additional courses after CR is confirmed.&#xD;
&#xD;
      Patients are followed every 8 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 4-8&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response or disease stabilization</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular changes with therapy</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be examined using logistic regression or Fisher's exact tests as appropriate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Adenocarcinoma of the Colon</condition>
  <condition>Adenocarcinoma of the Rectum</condition>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral erlotinib once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after CR is confirmed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the colon or rectum that&#xD;
             is not curable with conventional therapy&#xD;
&#xD;
               -  Recurrent or metastatic disease&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Target lesion must not be in a previously irradiated field unless progression of&#xD;
                  this lesion has been documented&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
          -  WBC at least 1,500/mm^3&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST or ALT no greater than 3 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
          -  Creatinine no greater than 1.25 times ULN&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No gastrointestinal tract disease resulting in an inability to take oral medication or&#xD;
             a requirement for IV alimentation&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No unresolved complete or subacute bowel obstruction&#xD;
&#xD;
          -  No severe enteropathy that would interfere with absorption of study drug&#xD;
&#xD;
          -  No abnormalities of the cornea:&#xD;
&#xD;
               -  Dry eye syndrome or Sjogren's syndrome&#xD;
&#xD;
               -  Congenital abnormality (e.g., Fuch's dystrophy)&#xD;
&#xD;
               -  Abnormal slit-lamp examination using a vital dye (e.g., fluorescein or&#xD;
                  Bengal-Rose)&#xD;
&#xD;
               -  Abnormal corneal sensitivity test (Schirmer test or similar tear production test)&#xD;
&#xD;
          -  No significant traumatic injury within the past 21 days&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study&#xD;
&#xD;
          -  No other concurrent uncontrolled illness that would preclude study&#xD;
&#xD;
          -  No other malignancy within the past 3 years except curatively treated nonmelanoma skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic disease with either&#xD;
             fluorouracil (5-FU) and oxaliplatin or 5-FU and a topoisomerase inhibitor (e.g.,&#xD;
             irinotecan), OR 5-FU (or other single-agent fluoropyrimidine, such as capecitabine)&#xD;
             followed by irinotecan for advanced disease&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption&#xD;
&#xD;
          -  No prior epidermal growth factor receptor-targeting therapy&#xD;
&#xD;
          -  No other concurrent investigational therapies&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent combination anti-retroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
&#xD;
               -  Low molecular weight heparin allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Oza</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital Phase 2 Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital Phase 2 Consortium</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

